Type 2 Diabetes Mellitus: Etiology, Pathogenesis and Clinical Manifestations

  • Yolanta T. Kruszynska


Type 2 diabetes mellitus affects about 3% of the population or 100 million people worldwide. The prevalence is higher in Europe and the USA, affecting 5–7% of the population and is increasing. Many cases (30% or more) are undiagnosed. Although common, its pathogenesis remains unclear. There are many reasons for this. Perhaps the most important is the heterogeneity of type 2 diabetes due in part to a variable interplay between genetic and environmental factors. Although the diagnosis rests on documentation of hyperglycemia it is important to appreciate that other metabolic abnormalities, for example disturbances of lipid metabolism, are also present and may precede the emergence of hyperglycemia (see Chapter VI.11). As depicted in Figure 1, overt hyperglycemia and the syndrome of type 2 diabetes is due to a variable combination of insulin resistance affecting the liver and peripheral insulin target tissues and of impaired insulin secretion. Since insulin resistance and abnormalities of insulin secretion may be associated with other pathologies, for example liver disease, renal disease, glucocorticoid, growth hormone or thyroid hormone excess, diabetes may be secondary to these conditions (see Chapter V.5).


Insulin Resistance Insulin Secretion Insulin Receptor Postprandial Hyperglycemia Impaired Insulin Secretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Froguel P, Velho G. Genetic determinants of type 2 diabetes. Recent Prog Horm Res 56: 91–105, 2001.PubMedCrossRefGoogle Scholar
  2. 2.
    Grundy SM. Metabolic complications of obesity. Endocrine 13: 155165, 2000.Google Scholar
  3. 3.
    Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1 (Suppl 1): S1 - S7, 1999.PubMedCrossRefGoogle Scholar
  4. 4.
    Clark DO. Physical activity efficacy and effectiveness among older adults and minorities. Diabetes Care 20: 1176–1182, 1997.PubMedCrossRefGoogle Scholar
  5. 5.
    Jung RT. Obesity and nutritional factors in the pathogenesis of noninsulin-dependent diabetes mellitus. In Pickup J, Williams G, Eds. Textbook of Diabetes, 2nd ed. Blackwell Science, Oxford, UK, pp 19.119. 23, 1997.Google Scholar
  6. 6.
    Yost TJ, Jensen DR, Haugen BR, Eckel RH. Effect of dietary macronutrient composition on tissue-specific lipoprotein lipase activity and insulin action in normal-weight subjects. Am J Clin Nutr 68: 296302, 1998.Google Scholar
  7. 7.
    Swinburn BA, Boyce VL, Bergman RN, Howard BV, Bogardus C. Deterioration in carbohydrate metabolism and lipoprotein changes induced by modern, high fat diet in Pima Indians and Caucasians. J Clin Endocrinol Metab 73: 156–165, 1991.PubMedCrossRefGoogle Scholar
  8. 8.
    Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 106: 329–333, 2000.PubMedCrossRefGoogle Scholar
  9. 9.
    Stern MP. Strategies and prospects for finding insulin resistance genes. J Clin Invest 106: 323–327, 2000.PubMedCrossRefGoogle Scholar
  10. 10.
    Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334: 777–783, 1996.PubMedCrossRefGoogle Scholar
  11. 11.
    Ferrannini E, Groop LC. Hepatic glucose production in insulin-resistant states. Diab Metab Rev 5: 711–725, 1989.CrossRefGoogle Scholar
  12. 12.
    Alberti KGMM. The clinical significance of impaired glucose tolerance. Diabet Med 13: 927–937, 1996.PubMedCrossRefGoogle Scholar
  13. 13.
    Gannon MC, Nuttall JA, Damberg G, Gupta V, Nuttall FQ. Effect of protein ingestion on the glucose appearance rate in people with type 2 diabetes. J Clin Endocrinol Metab 86: 1040–1047, 2001.PubMedCrossRefGoogle Scholar
  14. 14.
    Fagot-Campagna A. Emergence of type 2 diabetes mellitus in children: epidemiological evidence. J Pediatr Endocrinol Metab 13 (Suppl 6): 1395–402, 2000.PubMedGoogle Scholar
  15. 15.
    UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998.CrossRefGoogle Scholar
  16. 16.
    UK Prospective Diabetes Study Group. UK prospective diabetes study 16: Overview of 6 years ` therapy of type II diabetes: A progressive disease. Diabetes 44: 1249–1258, 1995.CrossRefGoogle Scholar
  17. 17.
    Kahn SE. The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 108 (Suppl 6a): 2S - 8S, 2000.PubMedCrossRefGoogle Scholar
  18. 18.
    Temple RC, Clark PM, Nagi DK, et al. Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol (Oxf)32: 689–693, 1990.Google Scholar
  19. 19.
    Porte D Jr, Kahn SE. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 50 (Suppl 1): S160–163, 2001.PubMedCrossRefGoogle Scholar
  20. 20.
    Reaven GM, Chen YDI, Hollenbeck CB, et al. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab 76: 44–48, 1993.PubMedCrossRefGoogle Scholar
  21. 21.
    Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in noninsulin-dependent diabetes. Diabetes 37: 736–744, 1998.CrossRefGoogle Scholar
  22. 22.
    Garvey WT, Olefsky JM, Griffin J, et al. The effects of insulin treatment on insulin secretion and action in type II diabetes mellitus. Diabetes 34: 222–234, 1985.PubMedCrossRefGoogle Scholar
  23. 23.
    Henry RR, Wallace P, Olefsky JM. The effects of weight loss on the mechanims of hyperglycemia in obese noninsulin-dependent diabetes mellitus. Diabetes 35: 990–998, 1986.PubMedCrossRefGoogle Scholar
  24. 24.
    McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42: 128–138, 1999.PubMedCrossRefGoogle Scholar
  25. 25.
    Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 16: 895–906, 1998.PubMedCrossRefGoogle Scholar
  26. 26.
    Cline GW, Petersen KF, Krssak M, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341: 240–246, 1999.PubMedCrossRefGoogle Scholar
  27. 27.
    Kruszynska YT, Mulford MI, Baloga J, Yu JG, Olefsky JM. Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47: 1107–1113, 1998.PubMedCrossRefGoogle Scholar
  28. 28.
    Thorburn AW, Gumbiner B, Bulacan F, et al. Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest 87: 489–495, 1991.PubMedCrossRefGoogle Scholar
  29. 29.
    DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15: 318–368, 1992.PubMedCrossRefGoogle Scholar
  30. 30.
    Kruszynska YT, Olefsky JM. Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Invest Med 44: 413–428, 1996.Google Scholar
  31. 31.
    Thies RS, Molina JM, Ciaraldi TP et al. Insulin receptor autophosphorylation and endogenous substrate phosphorylation in human adipocytes from control, obese and non-insulin dependent diabetic subjects. Diabetes 39: 250–259, 1990.PubMedCrossRefGoogle Scholar
  32. 32.
    Cusi K, Katsumi M, Osman A, et al. Insulin resistanceGoogle Scholar
  33. differentially affects the PI-3-kinase-and MAP kinase-mediated signaling in human muscle. J Clin Invest 105: 311–320, 2000.CrossRefGoogle Scholar
  34. 33.
    Kelley DE, Mintun MA, Watkins SC, et al. The effect of non-insulin dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 97: 2705–2713, 1996.PubMedCrossRefGoogle Scholar
  35. 34.
    Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest 95: 690–698, 1995.PubMedCrossRefGoogle Scholar
  36. 35.
    Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin dependent diabetes mellitus. N Engl J Med 321: 337–343, 1989.PubMedCrossRefGoogle Scholar
  37. 36.
    Yki-Jarvinen H. Glucose toxicity. Endocr Rev 13: 415–431, 1992.PubMedGoogle Scholar
  38. 37.
    Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 84: 3J - 10J, 1999.PubMedCrossRefGoogle Scholar
  39. 38.
    Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 16: 21–31, 1993.PubMedCrossRefGoogle Scholar
  40. 39.
    Hollenbeck CB, Reaven GM. Treatment of patients with non-insulindependent diabetes mellitus: Diabetic control and insulin secretion and action after different treatment modalities. Diabetic Med 4: 311–316, 1987.PubMedCrossRefGoogle Scholar
  41. 40.
    Virkamaki A, Ueki K, Kahn RC. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103: 931–943, 1999.PubMedCrossRefGoogle Scholar
  42. 41.
    Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 106: 459–465, 2000.PubMedCrossRefGoogle Scholar
  43. 42.
    Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49: 1367–1373, 2000.PubMedCrossRefGoogle Scholar
  44. 43.
    Wajngot A, Chandramouli V, Schumann WC, et al. Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. Metabolism 50: 47–52, 2001.PubMedCrossRefGoogle Scholar
  45. 44.
    Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 43: 946–952, 2000.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Yolanta T. Kruszynska

There are no affiliations available

Personalised recommendations